Nektar Therapeutics Announces New Data From Phase 2b Studies In Dermatitis And Alopecia Treatment Rezpegaldesleukin Has Been Accepted For Two Oral Presentations At The 2026 AAD Annual Meeting, March 27-31
Benzinga Newsdesk 7 months ago
News
Rezpegaldesleukin is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions.
Rezpegaldesleukin is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions. Rezpegaldesleukin works by targeting the IL-2 receptor complex and preferentially stimulating the proliferation of Treg cells without stimulating cytotoxic CD8+ T and CD4+ T cells, which drive autoimmune disease, to restore immune balance.